Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BT8009 in Nectin-4 expressing advanced malignancies
2023-509781-37-00Phase 2Authorised
- Sponsor
- Bicycle Therapeutics
- Start
- Apr 2021
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 6
01
Overview
Phase 2, open-label trial of zelenectide pevedotin and pembrolizumab in cancer (4 arms), sponsored by Bicycle Therapeutics. Primary endpoints: Incidence of treatment-emergent adverse events and safety abnormalities, Dose-limiting toxicities and 2 more. Planned start Apr 2021; status: authorised.
02
Drugs
zelenectide pevedotinpembrolizumab
03
Conditions
cancer
Beyond the preview
Go deeper on 2023-509781-37-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509781-37-00.